Cognetivity Neurosciences Ltd. (CGNSF)
| Market Cap | 94.00 -99.0% |
| Revenue (ttm) | 71.26K |
| Net Income | -6.22M |
| EPS | -0.07 |
| Shares Out | 93.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,000 |
| Open | 0.0001 |
| Previous Close | 0.0001 |
| Day's Range | 0.0001 - 0.0019 |
| 52-Week Range | 0.000001 - 0.0001 |
| Beta | 34.57 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Cognetivity Neurosciences
Cognetivity Neurosciences Ltd. operates as a technology company. It develops an integrated cognitive assessment, a cognitive testing platform for use in medical, commercial, and consumer environments that allows early diagnosis of dementia; and OptiMind, a wellness app. The company was formerly known as Utor Capital Corp. and changed its name to Cognetivity Neurosciences Ltd. in December 2017. Cognetivity Neurosciences Ltd. was incorporated in 2015 and is headquartered in Vancouver, Canada. [Read more]
News
CSE Bulletin: Delist - Cognetivity Neurosciences Ltd. (CGN)
Toronto, Ontario--(Newsfile Corp. - Le 29 mai/May 2025) - The common shares of Cognetivity Neurosciences Ltd. will be delisted from the CSE at market close today, May 29, 2025.
CognICA(TM) Shown to Save Tens of Millions of Dollars in Healthcare Costs Annually and Improve Patient Outcomes in the UK National Health Service
Latest Peer-Reviewed Study Published in Frontiers in Public Health Highlights Cost-Efficiency and Improved Clinical Outcomes from Using Cognetivity's Proprietary CognICA(TM) Technology, Showing Saving...
Cognetivity Neurosciences and UC Health Partner to Improve Early Detection of Cognitive Impairment in USA
Collaboration With Highly Rated Healthcare Provider Opens US Healthcare Market for Brain Health for AI Powered CognICA, Enabling Patient Access to Latest Alzheimer's Drugs Vancouver, British Columbia-...
Cognetivity Neurosciences Announces Commercial Agreement with Mediclinic to Provide Cognitive Assessment to Over 50s
Program Designed to Identify Age-Related Brain Health Issues at an Early Stage, Allowing Effective Provision of Coordinated Care Vancouver, British Columbia--(Newsfile Corp. - October 3, 2023) - Cogne...
Cognetivity Neurosciences Partners with No Fear Counselling to Pioneer Brain Health Assessment Through Groundbreaking AI Technology
New Approach to Measuring Impact of Counselling to Deliver Next Generation Care to Mental Health Sufferers in North America Vancouver, British Columbia--(Newsfile Corp. - September 21, 2023) - Cogneti...
Cognetivity Neurosciences' AI Powered CognICA Platform Wins Major Industry Award
CognICA Chosen as Winner of Best AI Product in Healthcare Award at CogX Festival Vancouver, British Columbia--(Newsfile Corp. - September 13, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: ...
Cognetivity Neurosciences' AI Powered CognICA Platform Shortlisted for Major Industry Award
CognICA Shortlisted for Most Innovative AI Product in Healthcare Award at CogX Festival Vancouver, British Columbia--(Newsfile Corp. - September 5, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (...
Cognetivity Neurosciences Announces Publication of Peer-Reviewed Article Showing Effectiveness of its AI Powered CognICA Technology in Detecting Early-Stage Alzheimer's Disease
Cognetivity's Landmark ADePT Study, Funded by the UK Innovation Agency and Published in Leading Neuroscience Journal Demonstrates Unprecedented Sensitivity in Detecting Cognitive Impairment in Early S...
Cognetivity Neurosciences Announces Successful Registration With Health Canada for Clinical use of CognICA(TM) AI-Powered Brain Health Technology in Canada
Approval opens up a new major market for CognICA, providing a solution to the urgent requirement for large-scale early detection and monitoring for the rollout of incoming Alzheimer's disease drugs Va...
New Disease Modifying Drug for Alzheimer's Disease Fully Approved by FDA, Highlighting the Crucial Role for Cognetivity in Early Detection and Monitoring
Vital breakthrough for Alzheimer's patients worldwide with Eisai's Leqembi FDA approval; Cognetivity Neurosciences' AI CognICA technology poised to play pivotal role in early detection and monitoring ...
Cognetivity Neurosciences Partners with Clairvo to Advance AI Powered Brain Health Management in Japan
Partnership will accelerate adoption of Cognetivity's AI platform in Japan and other Asia-Pacific territories Vancouver, British Columbia--(Newsfile Corp. - June 13, 2023) - Cognetivity Neurosciences ...
Cognetivity Neurosciences AI Platform Technology to Play a Pivotal Role in the Effective Delivery of Newly Approved Alzheimer's Drugs
US Medicare & Medicaid to require data collection as part of drug reimbursement Vancouver, British Columbia--(Newsfile Corp. - June 6, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF)...
Cognetivity Neurosciences Announces Collaboration with Alzheimer's Society to Further Expand its AI Algorithms
Agreement aims at further development of Cognetivity's AI (Artificial Intelligence) platform through investigating comorbidities in diabetes and dementia Vancouver, British Columbia--(Newsfile Corp. -...
Eli Lilly Releases Positive Results on Latest Disease Modifying Therapeutic for Alzheimer's Disease, Highlighting Need for Cognetivity's CognICA Platform
The news highlights the urgent need for more consistent, wide scale detection of the disease at an early stage Vancouver, British Columbia--(Newsfile Corp. - May 9, 2023) - Cognetivity Neurosciences L...
Cognetivity Neurosciences Announces Agreement with Mitsui Sumitomo Aioi Life Insurance of Japan to Provide CognICA Technology to Customers
Company to provide its AI-powered cognitive assessment technology to policyholders in Japanese market to promote proactive approach to brain health Vancouver, British Columbia--(Newsfile Corp. - April...
Cognetivity Neurosciences Appoints Renowned Life Sciences Leader Karimah Es Sabar as Director
Appointment brings deep industry and investment experience to the company, helping the company's expansion and growth globally Vancouver, British Columbia--(Newsfile Corp. - April 20, 2023) - Cognetiv...
Cognetivity Neurosciences Unveils Groundbreaking Research on Cognition and Sleep, Extends Collaboration with University of Oxford
Company presents key data on measuring impact of sleep disorders on brain health; University of Oxford extends collaboration on monitoring changes in cognition of older adults Vancouver, British Colum...
Cognetivity Neurosciences Enters Commercial Agreement with UK-Based Brain Health Supplements Provider
Agreement sees Cognetivity expand commercial offering into sports and fitness market, with cutting-edge assessment and monitoring technology made available to customers of brain health supplement subs...
Cognetivity Neurosciences Publishes Outstanding Results and Expands Deployment With Senior Care Network in Singapore
Expansion of first-phase deployment follows excellent published results, showing cross-cultural validity, leading to further expansion and market traction in Asia Vancouver, British Columbia--(Newsfil...
Cognetivity Neurosciences Announces Commercial Deployment at Leading Psychiatry and Neurology Centre in UAE
Latest Agreement Signals Continued, Rapid Commercial Growth in Middle East Region Vancouver, British Columbia--(Newsfile Corp. - February 23, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB:...
Cognetivity Announces Further Scientific Evidence of its AI-Powered CognICA(TM) Platform's Ability to Detect and Monitor Cognitive Impairment in Patients With Multiple Sclerosis
Peer-reviewed article demonstrates effectiveness of company's technology in major disease area with global application for the detection and monitoring of disease Vancouver, British Columbia--(Newsfil...
Cognetivity Neurosciences Releases Latest Version of AI-powered Brain Health Assessment Platform
With global interest in AI at an all-time high, latest update to Cognetivity's flagship medical device affirms company's sustained commitment to being at the forefront of AI in healthcareVancouver, Br...
Cognetivity Neurosciences' CognICA Platform Successfully Monitors Cognitive Performance in Alzheimer's Patients Receiving Disease-Modifying Therapy
Demonstrable sensitivity and clinical usability of Cognetivity's screening and monitoring tool leaves the company well placed to support the dawning era of targeted therapies for neurodegenerative dis...
Cognetivity Neurosciences Provides Update on 2022 Corporate Achievements
Key achievements in 2022 included continued collaboration with global pharmaceutical firms working in neurodegenerative disease, new and ongoing commercial deployments spanning three continents, and c...
Cognetivity Neurosciences' Brain Health Platform Cited as Case Study as Part of Early Dementia Detection Policy Recommendations by Alzheimer's Research UK
Policy paper published by UK's leading dementia research charity emphasizes importance of early detection in dementia diagnosis, citing Cognetivity's CognICA(TM) as an innovative solution for use in p...